Two Head-to-Head Randomized Trials Highlight Superior Early Patient Experience with the UroLift™ System for BPH1-2 First-Ever Analysis Utilizing the American Urological Association Quality Registry (AQUA) to Assess BPH Treatment Modalities Shows Strongest Symptom Improvement Score Shift with UroLift™ System at Three Months.3 First Study to Confirm Safety of Stabilized Hyaluronic Acid (sHA) Rectal Spacer in Cases with Rectal Wall Infiltration (RWI).4 WAYNE, Pa., May 15, 2025 (GLOBE NEWSWIRE) -- Teleflex Inc ...

Edwards Lifesciences (EW) 2025 Conference May 13, 2025 01:40 PM ET Speaker0 Travis Steed, the medical device analyst, and continuing our medical device conversations today. Next up, we have Edwards Lifesciences, Bernard Zevigian, if I said that right, CEO, and we got Scott Ullum, CFO. So great, thanks for coming. Good morning. Looking forward to the discussion. Speaker1 Pleasure to be here. Speaker0 Thank you. And so I I wanna open up with kind of a big picture question. And you've laid out commitments at t ...

Financial Data and Key Metrics Changes - Revenue in Q1 2025 was $896,000, up 39% compared to $647,000 in Q1 2024 [25] - Unit sales increased approximately 46% due to growth from patients with full insurance reimbursement coverage and the company's financial assistance program [25] - Gross margin in Q1 2025 was 84.4%, down from 88.4% in Q4 2024, attributed to a higher growth rate of discounted financial assistance patients [26][27] - Operating loss for Q1 2025 was $2,300,000, an increase of 25% compared to a $1,800,000 loss in Q1 2024 [29] Business Line Data and Key Metrics Changes - The company reported significant growth in the IV stim technology, with a 39% growth in Q1 2025 [9] - The rectal expulsion device (RED) received FDA clearance and is currently in a soft launch phase, expected to enhance revenue opportunities [15][21] Market Data and Key Metrics Changes - Total covered lives increased from approximately 4 million a year ago to about 51 million today, indicating a substantial expansion in market access [11] - The company is focused on achieving blanket insurance coverage and the implementation of a category one CPT code effective January 1, 2026, which is critical for scaling operations [10][14] Company Strategy and Development Direction - The company aims to achieve cash flow breakeven and profitability by focusing on insurance policy coverage and the category one CPT code [20][24] - The strategy includes leveraging strong published data to drive insurance expansion, leading to sustainable revenues and margins [8][20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued revenue growth due to the expected publication of guidelines and the implementation of the CPT code [32][34] - The company anticipates that as insurance coverage increases, the percentage of sales through full-price purchase orders will also rise, enhancing revenue potential [19][20] Other Important Information - The company is currently managing a legal settlement from 2019, which will be paid in installments starting January 2026, allowing the company to move forward without the burden of ongoing litigation [42][45] - The company has made strides in expanding its insurance coverage, which is expected to positively impact sales volume in the coming quarters [26] Q&A Session Summary Question: When do you expect the guidelines to be published? - Guidelines are expected to be published by the end of the month, which will lead to increased orders based on policy coverage [32][33] Question: How do you see your operating expenses in the near and medium term? - Operating expenses are expected to increase as investments in sales and marketing are necessary to meet upcoming demand, but as a percentage of sales, they are expected to decrease [35][37] Question: Can you provide more details on the RED technology? - The response to the RED technology has been stronger than expected, and the company is optimistic about its commercial execution despite the slow uptake in revenue [38][40] Question: Can you provide details on the legal settlement? - The legal settlement amounts to $750,000, to be paid in equal monthly installments starting January 2026, which the company views as a positive step to eliminate legal risks [42][45]

J P M O R G A N North America Equity Research 04 May 2025 J.P. Morgan MedTech What to Expect in the Week Ahead: Who Will Beat, Who Will Miss? MedTech earnings continue this week with ZBH as the only large-cap and BVS, Medical Supplies & Devices CBLL, CVRX, ENOV, HAE, IART, INSP, TMCI, TMDX, PODD, and SKIN on the SMid-cap side. In the comments below we've tried to summarize our thoughts and expectations going into some of the more consequential names. In addition, click here for a summary of each company's h ...

In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: U.S. GAAP Results (U.S. dollars in thousands, except for per share data) | | Q1 2025 | Q1 2024 | | --- | --- | --- | | Revenues | $77,874 | $80,284 | | Gross ...

Medtronic TodayMDTMedtronic$82.80 +1.00 (+1.22%) 52-Week Range$75.96▼$96.25Dividend Yield3.38%P/E Ratio25.17Price Target$96.14Add to WatchlistInvestors increasingly seek stable and resilient investments in today's volatile and economically uncertain market. Consequently, it is crucial to identify companies with strong fundamentals, defensive strategies, and dependable shareholder returns. Medtronic plc NYSE: MDT, a leading global healthcare technology company, stands out as a compelling option. It offers a ...